Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer. (BabyTears)

A

Andrea DeCensi

Status and phase

Begins enrollment in 3 months
Phase 2

Conditions

Breast Cancer

Treatments

Drug: Tamoxifen 10 MG
Drug: Exemestane 25 MG

Study type

Interventional

Funder types

Other

Identifiers

NCT06364267
BabyTears

Details and patient eligibility

About

The purpose of the study is to determine if 6 and 12 months of treatment with Tamoxifen at lower dose is superior to Exemestane at lower dose on quality of life.

Full description

It is a multicenter, randomized, double blind, superiority phase IIb trial. Eligible patients will be randomized with a 1:1 ratio into: ARM 1: BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months or unless progression, SAE, medical decision, patient withdrawal occur. ARM 2: BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 months or unless progression, SAE, medical decision, patient withdrawal occur. Blinding will be guaranteed by over-encapsulation of active tablet agents with an AA capsule in a 6-month bottle. In both arms, treatment should begin within 30 days from randomization. Tamoxifen and Exemestane will be provided for free by the Study Sponsor. After study completion, participants will be unblinded and treated according to local study guidelines. Clinical visit will be performed every 6 months (±14 days) with physical examination vital signs and weight and girth measurement, ECOG PS, MENQOL questionnaire (0, 6, 12 months), review of self-reported compliance, concomitant medications, AEs assessment, and physical exam. Telephone/video contact may be allowed at 3 and 9 months, whereas baseline, 6 months and 12 months visits are necessary for blood and stool collection and biomarker assessment. Blood serum and stool samples for centralized storage at IEO, Milan, Italy, will be collected at different time points.

Enrollment

160 estimated patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

Postmenopausal women, defined as amenorrhea for 6-12 months and FSH> 45 mU/mL, or amenorrhea for at least 12 months, and any of the following criteria:

Recent (within 12 months from date of consent form signature) histologic diagnosis of ER+ve (>5%) DCIS or diagnosis within 3 years of HRL (ADH, LCIS, ALH), or:

At least 3% breast cancer risk at 5 years (or 5% risk at 10yrs) per one of the following risk models: the Breast Cancer Surveillance Consortium risk calculator V3, the BCRAT model (https://tools.bcsc-scc.ucdavis.edu/BC5yearRisk/#/), or the CANRISK model (https://www.canrisk.org/), or Tyrer-CuzickmodelV8 (https://ibis-risk-calculator.magview.com/), or:

  • Known carriers of a germline pathogenic/likely pathogenetic variant in the following moderate penetrance genes (CHEK2 or ATM), or women with chest wall irradiation before age of 30 years.
  • Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0-1.
  • Able to swallow oral medications.
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Specifically, all cancers diagnosed since 3 years or longer except for breast and endometrial are eligible.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Women of all races and ethnic groups are eligible for this trial.
  • Mammography performed up to 6 months before the trial consent form signature.
  • DEXA performed up to 12 months before the trial consent form signature.

Adequate bone marrow, hepatic and renal functions within 12 months from the date of trial consent form signature as defined below:

  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelets ≥ 100,000/ mm3
  • Hemoglobin ≥ 10.0 g/ dL
  • Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN)
  • ALT and AST ≤ 3.0 x ULN
  • Serum creatinine ≤ 1.5 x ULN or eGFR ≥ 60 mL/ min/ 1.73 m2.

Exclusion criteria

1. Pre/perimenopausal women (amenorrhea < 6 months and FSH<45 mU/mL) are not eligible because of risk of uncontrolled ovarian stimulation with exemestane.

2. History of DVT or PE. 3. Endometrial cancer. 4. Macular disorders. 5. Inability to comply with study procedures. 6. Prior use of antiestrogens within 12 months from the date of the trial consent form signature.

7. Use of hormone replacement therapy (HRT) within 3 months from the date of the trial consent form signature.

8. Severe osteoporosis (T score <-2.5 at either spine or hip), or recent vertebral fracture (within 6 months) not treated with zolendronic acid or denosumab.

9. Participants receiving any medications or substances that are inhibitors or inducers of CYP450 2D6 should be carefully assessed. Selective serotonin reuptake inhibitors (SSRIs) are allowed although should be carefully registered and discouraged in de novo users, particularly fluoxetine, paroxetine, bupropion.

10. Certain anti-antimicrobials such as terbinafine and quinidine; and other medications like cinacalcet may reduce the effectiveness of tamoxifen.

11. Concomitant use of CYP3A4 inducer medication (rifampicin, phenytonin, carbamazepine, phenobarbital, and St. John's wort) is contraindicated.

12. Current use of warfarin. Antiaggregants and new oral anticoagulants are allowed.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

160 participants in 2 patient groups

ARM 1
Experimental group
Description:
BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months
Treatment:
Drug: Tamoxifen 10 MG
ARM 2
Experimental group
Description:
BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 months.
Treatment:
Drug: Exemestane 25 MG

Trial contacts and locations

1

Loading...

Central trial contact

Andrea U De Censi, MD; Davide S Corradengo, SC

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems